Curigliano G.[Author] - Search Results

Year	Number of Results
1996	3
1997	2
1998	2
1999	2
2000	6
2001	9
2002	7
2003	10
2004	10
2005	11
2006	10
2007	11
2008	3
2009	12
2010	9
2011	15
2012	18
2013	25
2014	27
2015	25
2016	24
2017	34
2018	35
2019	51
2020	79
2021	106
2022	101
2023	120
2024	109

1

Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.

Thomas A, Mayer EL, DeMichele A, Harbeck N, Curigliano G, Ignatiadis M, Adam V, Zhou Y, Brown TP, Gilham L, Chua BH, Kalinsky K, Wolff AC, O'Reilly S. Thomas A, et al. Among authors: curigliano g. J Clin Oncol. 2024 Oct 9:JCO2401080. doi: 10.1200/JCO.24.01080. Online ahead of print. J Clin Oncol. 2024. PMID: 39383501

2

Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance.

Lebedeva A, Belova E, Kavun A, Taraskina A, Bartoletti M, Bièche I, Curigliano G, Dupain C, Rios-Hoyo A, Kamal M, Luchini C, Poyarkov S, Le Tourneau C, Veselovsky E, Mileyko V, Ivanov M. Lebedeva A, et al. Among authors: curigliano g. Mol Diagn Ther. 2024 Oct 5. doi: 10.1007/s40291-024-00748-4. Online ahead of print. Mol Diagn Ther. 2024. PMID: 39368036

3

Developing combination therapies with biologics in triple-negative breast cancer.

Gaudio G, Martino E, Pellizzari G, Cavallone M, Castellano G, Omar A, Katselashvili L, Trapani D, Curigliano G. Gaudio G, et al. Among authors: curigliano g. Expert Opin Biol Ther. 2024 Oct 3:1-20. doi: 10.1080/14712598.2024.2408756. Online ahead of print. Expert Opin Biol Ther. 2024. PMID: 39360776 Review.

4

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.

Boscolo Bielo L, Guerini Rocco E, Trapani D, Zagami P, Taurelli Salimbeni B, Esposito A, Belli C, Crimini E, Venetis K, Munzone E, Fusco N, Criscitiello C, Marra A, Curigliano G. Boscolo Bielo L, et al. Among authors: curigliano g. ESMO Open. 2024 Oct 1;9(10):103731. doi: 10.1016/j.esmoop.2024.103731. Online ahead of print. ESMO Open. 2024. PMID: 39357123 Free article.

5

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer.

Quintana A, Saini KS, Vidal L, Peg V, Slebe F, Loibl S, Curigliano G, Schmid P, Cortes J. Quintana A, et al. Among authors: curigliano g. ESMO Open. 2024 Oct 1;9(10):103713. doi: 10.1016/j.esmoop.2024.103713. Online ahead of print. ESMO Open. 2024. PMID: 39357122 Free article. Review.

6

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Bardia A, et al. Among authors: curigliano g. N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407086. Online ahead of print. N Engl J Med. 2024. PMID: 39282896

7

Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?

Zagami P, Cortés J, Carey LA, Curigliano G. Zagami P, et al. Among authors: curigliano g. ESMO Open. 2024 Sep;9(9):103695. doi: 10.1016/j.esmoop.2024.103695. Epub 2024 Sep 9. ESMO Open. 2024. PMID: 39255535 Free PMC article. No abstract available.

8

Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives.

Ascione L, Castellano G, Curigliano G, Zagami P. Ascione L, et al. Among authors: curigliano g. Curr Opin Oncol. 2024 Sep 23;36(6):465-73. doi: 10.1097/CCO.0000000000001085. Online ahead of print. Curr Opin Oncol. 2024. PMID: 39246179 Free PMC article.

9

Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer.

Berton Giachetti PPM, Giordano E, Taurelli Salimbeni B, Trapani D, Curigliano G. Berton Giachetti PPM, et al. Among authors: curigliano g. Curr Opin Oncol. 2024 Jul 25. doi: 10.1097/CCO.0000000000001084. Online ahead of print. Curr Opin Oncol. 2024. PMID: 39246178

10

Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances.

Guidi L, Boldrini L, Trapani D, Curigliano G. Guidi L, et al. Among authors: curigliano g. Curr Opin Oncol. 2024 Aug 6. doi: 10.1097/CCO.0000000000001087. Online ahead of print. Curr Opin Oncol. 2024. PMID: 39246172

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

795 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

795 results

Results by year